title: Stenting in acute myocardial infarction.
abstract: The limitations (recurrent ischaemia, restenosis, reocclusion) of percutaneous transluminal coronary angioplasty (PTCA) in acute myocardial infarction (MI) can be addressed by stenting. The preliminary results of stenting are favourable (Stent PAMI, STENTIM, ZWOLLE trials). We report the results of the ICPS registry including 519 patients directly treated with angioplasty and stenting at the acute phase of myocardial infarction, with a repeat MI rate of 1% and a mortality of 3.7% in the non-shock group.
authors.affiliation: Institut Cardiovasculaire Paris Sud, Institut Hospitalier Jacques Cartier, Massy, France. morice-mc@lmn-tech.com
authors.forename: M C
authors.initials: MC
authors.lastname: Morice
authors.forename: T
authors.initials: T
authors.lastname: Lefèvre
authors.forename: Y
authors.initials: Y
authors.lastname: Louvard
authors.forename: P
authors.initials: P
authors.lastname: Dumas
authors.forename: C
authors.initials: C
authors.lastname: Loubeyre
mesh_terms: D015906:Angioplasty, Balloon, Coronary / Q000295:instrumentation / Q000379:methods*; D000925:Anticoagulants / Q000494:pharmacology; D020099:Coated Materials, Biocompatible; D017023:Coronary Angiography; D006493:Heparin / Q000494:pharmacology; D006801:Humans; D009203:Myocardial Infarction / Q000000981:diagnostic imaging / Q000401:mortality / Q000628:therapy*; D015607:Stents; D015996:Survival Rate; D016896:Treatment Outcome
chemical_list: D000925:Anticoagulants; D020099:Coated Materials, Biocompatible; D006493:Heparin